Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine
6 June 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
This document has been updated: Version 6 June 2022.
For translations of this document in other languages, click here.
Related links:
- Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine
- Latest GRADE and ETR tables
- Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine
Archived versions:
- Interim guidance for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Version 9 December 2021.
- Interim guidance for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Version 15 June 2021.
- Interim guidance for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Version 17 March 2021.
WHO Team
Immunization, Vaccines and Biologicals (IVB),
WHO Headquarters (HQ)
Editors
WHO
Number of pages
11
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/Ad26.COV2.S/2022.1
Copyright
